Saturday, 5 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Oracle Corporation (ORCL) Investors: Kessler Topaz Meltzer & Check, LLP Announces that the Firm has Filed a Securities Fraud Class Action Lawsuit Against Oracle Corporation and Encourages Investors to Contact the Firm

View original at globenewswire.com
Oracle Corporation (ORCL) Investors: Kessler Topaz Meltzer & Check, LLP Announces that the Firm has Filed a Securities Fraud Class Action Lawsuit Against Oracle Corporation and Encourages Investors to Contact the Firm RADNOR, Pa., Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OpenAI could account for more than a third of total Oracle revenues by fiscal 2028 and even a greater share by fiscal 2030

    80% confidence
  • Oracle's AI infrastructure strategy would result in massive increases in CapEx without equivalent, near-term growth in revenue; the Company's substantially increased spending created serious risks involving Oracle's debt and credit rating, free cash flow, and ability to fund its projects

    80% confidence
  • Oracle stock price target of $175, representing a 40% pullback

    80% confidence
  • OpenAI's ability to meet contractual obligations will be contingent on AI tailwinds continuing and its models being a market leader to continue to raise external financing

    80% confidence
  • Oracle expects to spend less than $100 billion on AI growth plans

    80% confidence
  • The Company's substantially increased spending on AI infrastructure would rapidly convert into accelerating revenue and profit growth

    80% confidence
  • Oracle's future lease exposure far exceeds similar commitments by peers, with a mismatch between the long duration of the property leases and much shorter contracts with key customers such as OpenAI

    80% confidence
  • Oracle has very good line-of-sight for capabilities to spend on CapEx right before it starts generating revenue

    80% confidence
  • Oracle really matters because it is the harbinger of the AI capex boom, and this repricing in debt markets is very consistent with the view that risks are building

    80% confidence
  • Blue Owl Capital pulled out of funding a $10 billion Oracle data center intended to serve OpenAI as a result of concerns about Oracle's spending commitments and rising debt levels

    80% confidence
  • Oracle's promises of massive new revenues from its increased AI infrastructure business were unlikely to materialize

    80% confidence
  • Oracle's $248 billion lease commitment disclosure is a bombshell disclosure, with lease commitments increasing massively from just under $100 billion in the prior quarter

    80% confidence
  • Oracle pushed back completion dates for data centers developing for OpenAI to 2028 from 2027 due to labor and material shortages

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Oracle Corporation (ORCL) Investors: Kessler Topaz Meltzer & Check, LLP Announces that the Firm has Filed a Securities Fraud Class Action Lawsuit Against Oracle Corporation and Encourages Investors to Contact the Firm — Source | Via News | ViaNews EU